Neutralizing Antibodies Limit Cell-Associated Spread of Human Cytomegalovirus in Epithelial Cells and Fibroblasts
Open Access
Abstract
Human cytomegalovirus (HCMV) can cause severe clinical disease in immunocompromised individuals, such as allograft recipients and infants infected in utero. Neutralizing activity of antibodies, measured as the ability to prevent the entry of cell-free virus, has been correlated with the reduction in HCMV transmission and the severity of HCMV-associated disease. However, in vivo HCMV amplification may occur mainly via cell-to-cell spread. Thus, quantifying the inhibition of cell-to-cell transmission could be important in the evaluation of therapeutic antibodies and/or humoral responses to infection or immunization. Here, we established a quantitative plaque reduction assay, which allowed for the measurement of the capacity of antibodies to limit HCMV spread in vitro. Using an automated fluorescence spot reader, infection progression was assayed by the expansion of viral plaques during the course of infection with various GFP-expressing viruses. We found that in contrast to non-neutralizing monoclonal antibodies (mAbs), neutralizing mAbs against both glycoprotein B and H (gB and gH) could significantly inhibit viral plaque expansion of different HCMV strains and was equally efficient in fibroblasts as in epithelial cells. In contrast, an anti-pentamer mAb was active only in epithelial cells. Taken together, our data demonstrate that specific anti-HCMV mAbs can significantly limit cell-associated virus spread in vitro.Keywords
Funding Information
- National Institutes of Health (1R21AI126886-01, 1R01AI089956-01)
This publication has 94 references indexed in Scilit:
- Impact of Sequence Variation in the UL128 Locus on Production of Human Cytomegalovirus in Fibroblast and Epithelial CellsJournal of Virology, 2013
- Rapid Intrahost Evolution of Human Cytomegalovirus Is Shaped by Demography and Positive SelectionPLOS Genetics, 2013
- Fetal Human Cytomegalovirus Transmission Correlates with Delayed Maternal Antibodies to gH/gL/pUL128-130-131 Complex during Primary InfectionPLOS ONE, 2013
- Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trialThe Lancet, 2011
- Sequential mutations associated with adaptation of human cytomegalovirus to growth in cell cultureJournal of General Virology, 2010
- Isolation of Human Monoclonal Antibodies That Potently Neutralize Human Cytomegalovirus Infection by Targeting Different Epitopes on the gH/gL/UL128-131A ComplexJournal of Virology, 2010
- Vaccine Prevention of Maternal Cytomegalovirus InfectionNew England Journal of Medicine, 2009
- Passive Immunization Reduces Murine Cytomegalovirus-Induced Brain Pathology in Newborn MiceJournal of Virology, 2008
- Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infectionVaccine, 2008
- UL74 of Human Cytomegalovirus Contributes to Virus Release by Promoting Secondary Envelopment of VirionsJournal of Virology, 2008